Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1021189 dose-finding trial in worsening HFpEF
NL-OMON40178Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vericiguat oral suspension in heart failure with preserved ejection fraction (HFpEF) (5 arms), sponsored by Bayer. Primary endpoints: Change from baseline to week 12 in left atrial volume and Change from baseline to week 12 in log-transformed NT-proBNP. Started Nov 2013; status: active, not recruiting.
02
Drugs
vericiguat oral suspension
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON40178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40178.